PINL:GRPOF - Post by User
Post by
Davesnothereon Apr 01, 2021 10:11pm
252 Views
Post# 32925979
Reminder
ReminderDr. Guy Chamberland, CEO and CRO of Tetra commented, "We are pleased to have successfully cleared this critical step in the NDS application. The application will now enter the next phase of review, thereby allowing Tetra to maintain its anticipated launching of REDUVO™ in the second half of 2021. This drug launch for Tetra is a major milestone as it moves the Company from a pre-revenue biotech to in revenue for 2021 which is great news for Tetra employees and shareholders.
Rock On !